Fady Ibraham Malik Cytokinetics Inc (CYTK) insider trading activity

Fady Ibraham Malik is EVP Research & Development of CYTOKINETICS INC. Currently has a direct ownership of 116,071 shares of CYTK, which is worth approximately $5.67 Million. The most recent transaction as insider was on May 12, 2022, when has been sold 13,987 shares (Common Stock) at a price of $9.65 per share, resulting in proceeds of $134,975. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 116K

4.01% 3M change

22.96% 12M change

Total Value Held $5.67 Million

Fady Ibraham Malik Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
May 12 2022	BUY Exercise of conversion of derivative security	$134,975 $9.65 p/Share	13,987 Added 7.13%	182,071 Common Stock
Apr 07 2022	SELL Open market or private sale	$985,642 $42.58 p/Share	23,148 Reduced 12.1%	168,084 Common Stock
Apr 07 2022	BUY Exercise of conversion of derivative security	$138,888 $6.0 p/Share	23,148 Added 10.8%	191,232 Common Stock
Mar 10 2022	SELL Open market or private sale	$1,015,543 $37.82 p/Share	26,852 Reduced 13.77%	168,084 Common Stock
Mar 10 2022	BUY Exercise of conversion of derivative security	$161,112 $6.0 p/Share	26,852 Added 12.11%	194,936 Common Stock
Mar 07 2022	SELL Payment of exercise price or tax liability	$365,206 $36.83 p/Share	9,916 Reduced 5.57%	168,084 Common Stock
Mar 02 2022	SELL Payment of exercise price or tax liability	$188,301 $37.63 p/Share	5,004 Reduced 3.27%	148,000 Common Stock
Mar 02 2022	BUY Grant, award, or other acquisition	-	30,000 Added 14.42%	178,000 Common Stock
Feb 28 2022	SELL Payment of exercise price or tax liability	$122,137 $35.32 p/Share	3,458 Reduced 2.21%	153,004 Common Stock
Feb 16 2022	BUY Grant, award, or other acquisition	-	7,148 Added 4.37%	156,462 Common Stock
Dec 09 2021	SELL Open market or private sale	$1,064,267 $36.49 p/Share	29,166 Reduced 16.34%	149,314 Common Stock
Dec 09 2021	BUY Exercise of conversion of derivative security	$183,746 $6.3 p/Share	29,166 Added 14.49%	172,053 Common Stock
Nov 11 2021	SELL Open market or private sale	$79,120 $39.56 p/Share	2,000 Reduced 1.33%	148,878 Common Stock
Oct 14 2021	SELL Open market or private sale	$75,460 $37.73 p/Share	2,000 Reduced 1.31%	150,878 Common Stock
Sep 09 2021	SELL Open market or private sale	$62,860 $31.43 p/Share	2,000 Reduced 1.29%	152,878 Common Stock
Aug 12 2021	SELL Open market or private sale	$65,200 $32.6 p/Share	2,000 Reduced 1.27%	154,878 Common Stock
Jul 08 2021	SELL Open market or private sale	$38,960 $19.48 p/Share	2,000 Reduced 1.26%	156,878 Common Stock
Jun 10 2021	SELL Open market or private sale	$42,960 $21.48 p/Share	2,000 Reduced 1.24%	158,878 Common Stock
May 13 2021	SELL Open market or private sale	$48,840 $24.42 p/Share	2,000 Reduced 1.23%	160,348 Common Stock
Apr 08 2021	SELL Open market or private sale	$46,780 $23.39 p/Share	2,000 Reduced 1.22%	162,348 Common Stock
Mar 11 2021	SELL Open market or private sale	$39,800 $19.9 p/Share	2,000 Reduced 1.2%	164,348 Common Stock
Mar 08 2021	SELL Payment of exercise price or tax liability	$146,496 $19.19 p/Share	7,634 Reduced 4.39%	166,348 Common Stock
Mar 02 2021	BUY Grant, award, or other acquisition	-	35,000 Added 16.75%	173,982 Common Stock
Mar 01 2021	SELL Payment of exercise price or tax liability	$54,399 $19.66 p/Share	2,767 Reduced 1.95%	138,982 Common Stock
Feb 26 2021	SELL Payment of exercise price or tax liability	$132,234 $18.73 p/Share	7,060 Reduced 4.74%	141,749 Common Stock

Also insider at

RCKT

ROCKET PHARMACEUTICALS, INC. Healthcare

FIM